Who we are
ODDIFACT is an AI-driven biotechnology company focused on enabling the emergence of new treatments for rare diseases. We activate underused academic and biomedical research to build regulatory-ready therapeutic programs—designed for partners to advance into development.
Today, our pipeline is biologics-first, while our platform is built to expand across modalities over time.
What we do
Our platform analyzes existing molecules and scientific evidence to identify high-potential indications. We convert these opportunities into structured, evidence-backed program packages and advance them through the Orphan Drug Designation pathway—then collaborate with pharmaceutical partners who take programs forward into clinical development, regulatory approval, and commercialization.
Learn about FDA Orphan drug designation program